focusing on the development and commercialization of "High Barrier to Entry" generic drugs. TWi focuses primarily on the development of Paragraph IV and high technical barrier generic drugs requiring strong science and technical know-how, as well as under-serviced mature molecules to meet market needs. For more information about TWi Corporate and "High Barrier to Entry" generics, please click here to visit www.twipharma.com. Our goals are to expand our market presence in the United States as a strong industry partner, and to continue to identify, acquire, develop, license and launch technically challenging or mature molecule generic drugs.
View Top Employees from TWi Pharmaceuticals, Inc.Website | http://www.twipharma.com |
Revenue | $11 million |
Employees | 76 (68 on RocketReach) |
Founded | 2010 |
Address | 115 West Century Road Suite 135, Paramus, New Jersey 07652, US |
Phone | +886 3 433 6438 |
Technologies |
JavaScript,
PHP,
ASP.NET
+3 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Manufacturing General, Pharmaceutical, Drug Discovery, Manufacturing, Health Care, Pharmaceuticals |
Web Rank | 6 Million |
Keywords | Twi Pharmaceuticals Inc, 安成 |
Competitors | Chiesi USA, Inc., Consilient Health, Elorac, Inc, Poniard Pharmaceuticals , Inc., Prasco |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular TWi Pharmaceuticals, Inc. employee's phone or email?
The TWi Pharmaceuticals, Inc. annual revenue was $11 million in 2024.
Rick Pallokat is the President of TWi Pharmaceuticals, Inc..
68 people are employed at TWi Pharmaceuticals, Inc..
TWi Pharmaceuticals, Inc. is based in Paramus, New Jersey.
The NAICS codes for TWi Pharmaceuticals, Inc. are [3254, 32541, 32, 325].
The SIC codes for TWi Pharmaceuticals, Inc. are [28, 283].